Table 4.
Number and proportion of subjects developing a ≥ 4-fold rise in serologic or ALS responses following controlled human infection with ETEC strain B7A.
| Study Group |
|||||
|---|---|---|---|---|---|
| Antigen | Assay | anti-CS6 (N = 19) n (%) |
anti-B7A (N = 20) n (%) |
Placebo (N = 20) n (%) |
All (N = 59) n (%) |
| Coli Surface Antigen 6 (CS6) | Serology (IgA) | 1 (5.3%) | 0 (0.0%) | 3 (15.0%) | 4 (6.8%) |
| Serology (IgG) | 1 (5.3%) | 3 (15.0%) | 6 (30.0%) | 10 (16.9%) | |
| ALS (IgA) | 2 (10.5%) | 2 (10.0%) | 6 (30.0%) | 10 (16.9%) | |
| ALS (IgG) | 1 (5.3%) | 3 (15.0%) | 6 (30.0%) | 10 (16.9%) | |
| Heat-Labile Toxin (LT) | Serology (IgA) | 6 (31.6%) | 1 (5.0%) | 10 (50.0%) | 17 (28.8%) |
| Serology (IgG) | 12 (63.2%) | 7 (35.0%) | 12 (60.0%) | 31 (52.5%) | |
| ALS (IgA) | 4 (21.1%) | 2 (10.0%) | 5 (25.0%) | 11 (18.6%) | |
| ALS (IgG) | 7 (36.8%) | 4 (20.0%) | 7 (35.0%) | 18 (30.5%) | |
| Lipopolysaccharide (LPS) Type 0148 | Serology (IgA) | 14 (73.7%) | 11 (55.0%) | 15 (75.0%) | 40 (67.8%) |
| Serology (IgG) | 7 (36.8%) | 8 (40.0%) | 10 (50.0%) | 25 (42.4%) | |
| ALS (IgA) | 19 (100.0%) | 16 (80.0%) | 18 (90.0%) | 53 (89.8%) | |
| ALS (IgG) | 13 (68.4%) | 11 (55.0%) | 14 (70.0%) | 38 (64.4%) | |